Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Iq-ai Limited LSE:IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 8.75 14,361 08:00:00
Bid Price Offer Price High Price Low Price Open Price
8.50 9.00 8.75 8.75 8.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 0.27 -0.62 -0.50 14
Last Trade Time Trade Type Trade Size Trade Price Currency
08:29:03 O 11,800 8.525 GBX

Iq-ai (IQAI) Latest News

More Iq-ai News
Iq-ai Investors    Iq-ai Takeover Rumours

Iq-ai (IQAI) Discussions and Chat

Iq-ai Forums and Chat

Date Time Title Posts
02/3/202118:12Imaging Quantification - Artificial Intelligence6,571
19/2/202111:08Colwyn Bay Free23

Add a New Thread

Iq-ai (IQAI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:29:058.5311,8001,005.95O
08:28:128.532,561218.33O
2021-03-02 16:15:358.5330,9172,635.67O
2021-03-02 15:55:218.535,749490.10O
2021-03-02 15:53:338.536,454550.53O
View all Iq-ai trades in real-time

Iq-ai (IQAI) Top Chat Posts

DateSubject
03/3/2021
08:20
Iq-ai Daily Update: Iq-ai Limited is listed in the General Retailers sector of the London Stock Exchange with ticker IQAI. The last closing price for Iq-ai was 8.75p.
Iq-ai Limited has a 4 week average price of 8p and a 12 week average price of 7.75p.
The 1 year high share price is 22.75p while the 1 year low share price is currently 1.95p.
There are currently 160,522,649 shares in issue and the average daily traded volume is 992,302 shares. The market capitalisation of Iq-ai Limited is Ā£14,045,731.79.
23/2/2021
13:49
greyseal: I am assuming that TB is selling more shares so that he can convert more CLNs. The latest declaration was 09/12/2020 when he converted £90,000 of the May 2019 CLNs. This leaves him with £160,000 May 2019 CLNs, which converts to 11.6m shares. I have just added up all of the round number share sells of 100,000 or more and got to around 11m. If we assume 75% of this sells relate to TB he hopefully only has 2-3m shares to off load, which could be cleared in the next week or so. At which point we should see share price be released. All IMHO
19/2/2021
11:08
swan86: Replying to @TopTradersADVFN Bayer tweet #IQAI @IQAI_IB Bayer AG @Bayer hxxp://Leverkusenbayer.com Joined April 2010 2,324 Following https://twitter.com/IQAI_IB/status/1362517778809389058?s=20 178K Followers
05/2/2021
05:59
hail67: IQAI on Arterys being rolled out in Nordics via Human BytesThu 21:44 Arterys has announce a new partnership with Human Bytes for the Nordic region. Arterys use IQAI as the basis for a number of products and sell IQAI on their platform. hxxps://www.linkedin.com/posts/human-bytes_human-bytes-to-partner-with-san-francisco-ugcPost-6759780787886833664-gmUO
04/2/2021
15:20
hail67: #IQAI IQ-AI - Imaging Biometrics @IQAI_IB https://twitter.com/IQAI_IB/status/1357347267666055171?s=20 2m @IQAI_IB has invested in additional AI computing horsepower to compress model development timelines for new products and technologies. Amazing speed!
25/1/2021
06:19
hail67: #IQAI https://twitter.com/IQAI_IB/status/1353555016733220864?s=20 https://twitter.com/IQAI_IB/status/1353556634640003073?s=20
07/1/2021
14:45
greyseal: Why would we have two Price Monitoring messages when the share price hasn't moved and virtually no shares traded?
06/1/2021
10:53
howdlep: Three excellent posts by VP007 over on LSE. I have combined them here so I can provide a link from Twitter as well:- Incase any investors missed this, I think 2021 will be the year IQAI capitalise on the sevens fold growth of the Telehealth market in the US. Source: hxxps://www.healtheuropa.eu/explosion-in-telehealth-market-due-to-covid-19/100127/ From the 2020 Half Year Report: Teleradiology and Expanding Distribution Since the inception of IQ-AI's subsidiary, Imaging Biometrics™, LLC ("IB, the foundational architectural design strategy of the products has been to build them as platform independent plugins. Steadfast in this approach, IB has successfully translated advanced technologies into portable clinical solutions that readily extend the base functionality of established workstations, medical viewing stations, PACS, and servers. A logical application of the platform-independent design of IB's products is in telehealth. With the onset of Covid-19, healthcare providers had to find new ways to stay connected with patients and administer care. The field of telehealth is exploding and is, for all intents and purposes, and untapped market. During the review period, three licenses of IB Neuro were deployed specifically in teleradiology application. While IB's current products readily lend themselves as natural value-add extensions to established teleradiology platforms, the Company is exploring more direct applications and platforms in the rapidly emerging telehealth space. Watch this space as this could lead to exponential growth for the company... Let’s recap why the share price is completely undervalued. The company has the following products: On the market: IB Clinic 2.0 - FDA, CE Approved IB Clinic consists of perfusion weighted imaging and permeability computation modules IB Neuro and IB DCE, diffusion weighted imaging analysis module IB Diffusion, image co-registration and manipulation module IB Delta Suite, and IB Rad Tech, which streamlines and automates customizable workflows. StoneChecker 2.0 - Approved for US, Europe and South Korea Recently upgraded based on potential client feedback and AI workflows to be included in the next upgrade early this year. Liver Surface Nodularity (LSN) Software - FDA and CE approved LSN's proprietary algorithms process CT images of a patient's liver to assess the nodules along the liver surface. This virtual biopsy offers a low cost, low-risk, non-invasive alternative that may aid in the staging of CLD and has the potential to become the standard of care for a significant global market. IB Stroke - FDA and CE approved A key differentiator for IB Stroke resides in the core Imaging Biometrics' ("IB") algorithms that will be used to generate output commonly used for stroke assessment. Specifically, the ability to automatically quantify blood volume and other perfusion parameters is unique to IB. The initial launch of IB Stroke will be within an IB Rad Tech workflow, which is already installed at leading neurological centres. In the pipeline: IB CAD IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed. IB Trax - in partnership with the Mayo Clinic This application will leverage the proven ability of quantitative Delta T1 maps, among other technologies, and focus on an improved workflow for evaluating both brain metastases and primary brain cancer across time. For almost a decade, IB's medical advisors and end-users of IB Neuro have considered that the manually intensive way currently used to longitudinally assess brain lesions is cumbersome and prone to error. IB Trax represents an efficient and streamlined platform that will address a significant and immediate need for routine clinical use. Gad Free Imaging Another disruptive technology under development by the Company is the ability to generate a contrast-free MRl image that is equivalent to one acquired with contrast. AI networks have been created and are being trained using only anatomical and functional images free of any exogenous contrast material. The ability to completely eliminate the administration of contrast material has significant benefits on multiple levels. Along with substantial financial savings that can be realised, the on-going concerns about the long-term effects of gadolinium deposition throughout the body can be avoided. Telehealth Since the inception of IQ-AI's subsidiary, Imaging Biometrics™, LLC ("IB, the foundational architectural design strategy of the products has been to build them as platform independent plugins. Steadfast in this approach, IB has successfully translated advanced technologies into portable clinical solutions that readily extend the base functionality of established workstations, medical viewing stations, PACS, and servers. A logical application of the platform-independent design of IB's products is in telehealth. With the onset of Covid-19, healthcare providers had to find new ways to stay connected with patients and administer care. The field of telehealth is exploding and is, for all intents and purposes, and untapped market. During the review period, three licenses of IB Neuro were deployed specifically in teleradiology application. While IB's current products readily lend themselves as natural value-add extensions to established teleradiology platforms, the Company is exploring more direct applications and platforms in the rapidly emerging telehealth space. Distribution / Partnerships Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, Arterys, aycan Medical Systems, Pixmeo Grants IB received a five-year, $2.57 million, NIH grant award in collaboration with The Barrow Neurological Institute (BNI), the Mayo Clinic in Arizona, and the Medical College of Wisconsin (MCW). This award follows the previously announced five-year, $2.8 million award IB received in late 2019. Together, these grants provide long-term funding to execute the respective goals and, at current staffing levels, subsidise over 60% of IB's development costs. Additional grants have been submitted to the NIH. All of their products are targeted at $bn markets... ...so taking into consideration all of the above...it’s hard not to believe that the share price will be multiples of where it is today.
04/12/2020
19:56
iambix: I don't think that Trevor Brown and the other directors intend to sell any of their shares. The reason being that their holdings are so large that the share price would crash if they did, and they would all be acting against themselves. Their plan will be to see if IQAI's products sell well over the next year. If this happens, they intend to put the company up for sale and get a much better price for their shareholdings. They control nearly half the company, so it would be easy for them to sell it. I think the share price will remain at about 10p for several months now, until next Summer when we learn the sales figures. I expect that the directors plan for IQAI to be sold off within the next three years.
22/11/2020
04:07
leadersoffice: Don't you just love Tesla lol. What's best about it is not just the cars but it's knowing that all those sad shorters got so burnt trying to undermine the companies share price. How do you think it will fare in the S&P 500? Some analysts think the share price could be volatile either way. Just invested in Nio. They've just had a brokers upgrade and potentially the next Tesla.
20/11/2020
12:21
master rsi: IQAI RESUME - Starting point to go ballistic 04 November 2020 - LSN Software Receives FDA Clearance IQ-AI today announces that the US Food and Drug Administration ("FDA") has granted 510(k) market clearance for the Liver Surface Nodularity ("LSN") software application. Earlier this year, IQ-AI's subsidiary, Imaging Biometrics, LLC ("IB"), entered into a business agreement with the owners of LSN, AI Metrics, LLC, which granted IB global rights to manufacture, market, and distribute the LSN software platform. Now that the FDA has granted market clearance, IB and AI Metrics will begin to actively market and sell LSN in the USA. CE mark for European distribution and commercialisation is expected later this quarter. LSN presents a new way to use CT scans for virtual liver biopsy to help assess individuals with chronic liver disease ("CLD"). CLD is a serious condition that progresses through various stages including liver inflammation, early fibrosis, advanced fibrosis, and cirrhosis. In total, over 2 billion people worldwide have some form of CLD which requires frequent monitoring for proper staging and treatment. Currently, the best way to monitor liver deterioration due to CLD is by undergoing a liver biopsy. The problem with liver biopsies is that they can be quite painful to the patient and expensive. A single liver biopsy can cost between $2,000 and $3,000 per test and is associated with a risk of bleeding. Biopsy sampling is also prone to errors which may result in misdiagnosis. LSN's proprietary algorithms process CT images of a patient's liver to assess the nodules along the liver surface. This low cost, low-risk, non-invasive procedure provides physicians with new information that may aid in the staging of CLD and has the potential to become the standard of care for a significant global market. -------------- 09 November 2020 / Q-AI Limited (IQAI.L) IB and the Mayo Clinic enter into an Agreement Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI, Ltd, has entered into an agreement (the “Agreement”) with Mayo Clinic to develop a brain lesion tracking platform, IB Trax. The collaboration’s objective is the development of an innovative AI technology to track metastatic and primary brain tumours. IB’s proven quantitative technologies will form the foundation of IB Trax and the overall workflow will receive direct clinical input from the Mayo Clinic. This Agreement considerably expands the existing relationship between IB and the Mayo Clinic by appointing Dr. Leland Hu, MD, an Assistant Professor of Radiology at the Mayo Clinic Arizona, to IB’s Scientific Advisory Board. Under the terms of the Agreement, IQ-AI will issue Mayo Clinic a token of $50,000 of shares in IQ-AI at a price equivalent to the three-month average share price prior to the effective date of the Agreement. In addition, IQ-AI will issue the Mayo Clinic, $10,000 of shares in IQ-AI at a price equivalent to the three-month average share price prior to the date the shares are issued, on the first anniversary and every successive year whilst the agreement is in existence. In addition, the Mayo Clinic will receive a 4% on-going royalty on each sale of IB Trax, including $20,000 on the initial commercial installation. Ultimately, the aim is to leverage IB’s existing quantitative solutions and AI expertise to develop a streamlined workflow that systematically identifies, tracks, and reports changes to brain lesions. Currently, the way clinicians perform this task is cumbersome and subjective. The Mayo Clinic is ideally positioned to assist in this effort as it is renowned for excellence and commonly treats the most challenging of brain tumour cases from around the world. “We are excited to team up with the Mayo Clinic to significantly expand the diagnostic utility of our core applications. This collaboration provides key clinical input to further enhance the design and guide development of IB Trax,” said Michael Schmainda, CEO of IB. Trevor Brown CEO of IQAI, commented, “IB have now entered a period of exponential growth in their development of innovative medical AI technologies.” ABOUT Imaging Biometrics , LLC Imaging BiometricsĀ®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com .
Iq-ai share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IQAI
Iq-ai
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210303 08:54:41